Dasatib 70 mg (dasatinib) is a targeted tyrosine kinase inhibitor (TKI) used to treat specific blood cancers, including Philadelphia chromosome-positive (Ph+), chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). It inhibits abnormal proteins, slowing cancer cell growth, inducing remission, and improving survival rates for patients resistant to other therapies.